Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (01-10)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	10588888
Filing Date	2007-04-06
First Named Inventor	Drew M. Pardoll
Art Unit	N/A 1635
Examiner Name	Not Yet Assigned Terra C. Gibbs
Attorney Docket Number	62763(71699)

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TCG/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	10588888
Filing Date	2007-04-06
First Named Inventor	Drew M. Pardoll
Art Unit	N/A 1635
Examiner Name	Not Yet Assigned Terra C. Gibbs
Attorney Docket Number	62763(71699)

	1	TSENG, S.Y. et al. "B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells." J Exp Med. 2001 Apr 2;193(7):839-46.	☐
	2	ZUFFEREY, R. et al. "Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery." J Virol. 72, 9873-80 (1998).	☐
	3	BORGES, L. et al. "Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo." J Immunol. 1999 Aug 1;163(3):1289-97.	☐
	4	MARSHALL, J.L. et al. "Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses." J Clin Oncol. 2000 Dec 1;18(23):3964-73.	☐
	5	MORSE, M.A. et al. "Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA." Cancer Invest. 2003 Jun;21(3):341-9.	☐
	6	RIDGWAY, D. "The first 1000 dendritic cell vaccinees." Cancer Invest. 2003;21(6):873-86.	☐
	7	LEVERKUS, M. et al. "Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis." Blood. 2000 Oct 1;96(7):2628-31.	☐
	8	McLELLAN, A. et al. "MHC class II and CD40 play opposing roles in dendritic cell survival." Eur J Immunol. 2000 Sep;30(9):2612-9.	☐
	9	WONG, B.R. et al. "TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor." J Exp Med. 1997 Dec 15;186 (12):2075-80.	☐
	10	EGGERT, A.A. et al. "Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration." Cancer Res. 1999 Jul 15;59(14):3340-3345.	☐
	11	CAYEUX, S. et al. "Direct and indirect T cell priming by dendritic cell vaccines." Eur J Immunol. 1999 Jan;29 (1):225-234.	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TCG/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	10588888
Filing Date	2007-04-06
First Named Inventor	Drew M. Pardoll
Art Unit	N/A 1635
Examiner Name	Not Yet Assigned Terra C. Gibbs
Attorney Docket Number	62763(71699)

	12	HAYAKAWA, Y. et al. "NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy." J Immunol. 2004 Jan 1;172(1):123-9.	☐
	13	KAMATH, A.T. et al "Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs." Blood. 2002 Sep 1;100(5):1734-41.	☐
	14	CAMPOREALE, A. et al. "Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes." Cancer Res. 2003 Jul 1;63(13):3688-94.	☐
	15	GORSKI, K. et al. "A set of genes selectively expressed in murine dendritic cells: utility of related cis-acting sequences for lentiviral gene transfer." Mol Immunol. 2003 Sep;40(1):35-47.	☐
	16	CHENG, L.E. et al. "Functional redundancy of the Nur77 and Nor-1 orphan steroid receptors in T-cell apoptosis." EMBO J. 1997 Apr 15;16(8):1865-75.	☐
	17	LIU, Z.G. et al. "Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the immediate-early gene nur77." Nature. 1994 Jan 20;367(6460):281-4.	☐
	18	KIM, S.O. et al. "Orphan nuclear receptor Nur77 is involved in caspase-independent macrophage cell death." J Exp Med. 2003 Jun 2;197(11):1441-52.	☐
	19	KUANG, A.A. et al. "Nur77 transcription activity correlates with its apoptotic function in vivo." Eur J Immunol. 1999 Nov;29(11):3722-8.	☐
	20	BRENNER, C. et al. "Mitochondria-the death signal integrators." Science. 289,1150-1 (2000).	☐
	21	LI, H. et al. "Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3." Science. 2000 Aug 18;289(5482):1159-64.	☐
	22	NOPORA, A. et al. "Bel-2 controls dendritic cell longevity in vivo." J Immunol. 169, 30006-14 (2002).	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TCG/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	10588888
Filing Date	2007-04-06
First Named Inventor	Drew M. Pardoll
Art Unit	N/A 1635
Examiner Name	Not Yet Assigned Terra C. Gibbs
Attorney Docket Number	62763(71699)

	23	PIRTSKHALAISHVILI, G. et al. "Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice." J Immunol. 2000 Aug 15;165(4):1956-64.	☐
	24	SOTOMAYOR, E.M. et al. "In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance." Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11476-81.	☐
	25	STAVELEY-O'CARROLL, K. et al. "Induction of antigen-specific T cell anergy: An early event in the course of tumor progression." Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1178-83.	☐
	26	ADLER, A.J. et al. "CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells." J Exp Med. 1998 May 18;187(10):1555-64.	☐
	27	DALYOT-HERMAN, N. et al. "Reversal of CD8+ T cell ignorance and induction of anti-tumor immunity by peptide-pulsed APC." J Immunol. 2000 Dec 15;165(12):6731-7.	☐
	28	STROME, S.E. et al. "Strategies for antigen loading of dendritic cells to enhance the antitumor immune response." Cancer Res. 2002 Mar 15;62(6):1884-9.	☐
	29	SCHNURR, M. et al. "Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells." Cancer Res. 2002 Apr 15;62(8):2347-52.	☐
	30	LAMBERT, L.A. et al. "Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole cell tumor antigens." J Immunother. 2001 May-Jun;24(3):232-6.	☐
	31	ASAVAROENGCHAI W., et al. "Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery." Proc Natl Acad Sci U S A. (2002) Jan 22;99(2):931-6	☐
	32	PARAJULI, P. et al. "Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets." Exp Hematol. 2001 Oct;29(10):1185-93.	☐
	33	FONG, L. et al. "Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy." Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8809-14.	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TCG/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	10588888
Filing Date	2007-04-06
First Named Inventor	Drew M. Pardoll
Art Unit	N/A 1635
Examiner Name	Not Yet Assigned Terra C. Gibbs
Attorney Docket Number	62763(71699)

	34	GILLIET, M. et al. "The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor." J Exp Med. 2002 Apr 1;195(7):953-8.	☐
	35	DIEHL, L. et al. "CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy." Nat Med. 1999 Jul;5(7):774-9.	☐
	36	SOTOMAYOR, E.M. et al. "Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40." Nat Med. 1999 Jul;5(7):780-7.	☐
	37	CUI, Y. et al. "Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells." Nat Med. 2003 Jul;9(7):952-8	☐
	38	GUERDER, S. et al. "A fail-safe mechanism for maintaining self-tolerance." J Exp Med. 1992 Aug 1;176(2):553-64	☐
	39	SPARWASSER, T. et al. "Bacterial DNS and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells." Eur J Immunol. 28, 2045-54 (1998)	☐
	40	BAUER, M. et al. "Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells." J Immunol. 2001 Apr 15;166(8):5000-7.	☐
	41	KADOWAKI, N. et al. "Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN." Immunol. 2001 Feb 15;166(4):2291-5.	☐
	42	PARK, Y. et al. "Cutting Edge: CpG DNA inhibits dendritic cell apoptosis by up-regulating cellular inhibitor of apoptosis proteins through the phosphatidylinositide-3'-OH kinase pathway." J Immunol. 2002 Jan 1;168(1):5-8.	☐
	43	MERAD, M. et al. "In vivo manipulation of dendritic cells to induce therapeutic immunity." Blood. 2002 Mar 1;99 (5):1676-82.	☐
	44	DOXSEE, C. et al. "The immune response modifier and Toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-alpha production in CD11c+CD11b+CD8- dendritic cells." J Immunol. 2003 Aug 1;171(3):1156-63.	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TCG/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10588888
	Filing Date	2007-04-06
	First Named Inventor	Drew M. Pardoll
	Art Unit	N/A 1635
	Examiner Name	Not Yet Assigned Terra C. Gibbs
	Attorney Docket Number	62763(71699)

	45	GIBSON, S.J. et al. "Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod." Cell Immunol. 2002 Jul-Aug;218(1-2):74-86.	☐
	46	NAKANO, H. et al. "CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells." J Exp Med. 2001 Oct 15;194(8):1171-8.	☐
	47	SHEN, Z. et al. "Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules." J Immunol. 1997 Mar 15;158(6):2723-30.	☐
	48	LANGENKAMP, A. et al. "Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells." Nat Immunol. 2000 Oct;1(4):311-6.	☐
	49	MATZINGER, P. et al. "The JAM test. A simple assay for DNA fragmentation and cell death." J Immunol Methods. 1991 Dec 15;145(1-2):185-92.	☐
	50	BORRELLO, I. et al. "Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines." Blood. 2000 May 15;95(10):3011-9.	☐

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	05/22/2011

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TCG/